Literature DB >> 3555028

Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.

H R Stutman, I Shalit, M I Marks, R Greenwood, S A Chartrand, B C Hilman.   

Abstract

Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks. Pharmacokinetic data were collected on Days 1, 7, and 14. Pharmacokinetic analyses revealed minor differences between the dosage regimens, and results were similar on the first, seventh, and last day of therapy. Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis. Sputum concentrations approximated serum values.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3555028

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.

Authors:  A G Arguedas; J C Akaniro; H R Stutman; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Type III Secretion System Gene Expression by Stimulating rsmYZ Transcription.

Authors:  Shubham Chakravarty; Cameron N Melton; Adam Bailin; Timothy L Yahr; Gregory G Anderson
Journal:  J Bacteriol       Date:  2017-10-31       Impact factor: 3.490

3.  Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.

Authors:  Kate H Regan; Jayesh Bhatt
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

4.  Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.

Authors:  M J Montgomery; P M Beringer; A Aminimanizani; S G Louie; B J Shapiro; R Jelliffe; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 7.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

8.  Serum levels of ciprofloxacin after single oral doses in patients with septicemia.

Authors:  M D'Espine; F Bellido; J C Pechère; R Auckenthaler; P Rohner; D Lew; B Hirschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

9.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.

Authors:  B A Christensson; I Nilsson-Ehle; B Ljungberg; A Lindblad; A S Malmborg; L Hjelte; B Strandvik
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Oral anti-pseudomonal antibiotics for cystic fibrosis.

Authors:  Tracey Remmington; Nikki Jahnke; Christian Harkensee
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.